A Dark Vector Cognition product

Item 1A. RISK FACTORS

5K characters. Original on sec.gov ·

Item 1A. RISK FACTORS

The 1 table in Item 1A. RISK FACTORS as one CSV, figures in aligned columns. For subscribers: paste your API key. One API call. Plans from $19 a month, see pricing.

An investment in our common stock involves risks. Before making an investment decision, you should carefully

consider all the information within Part I, Item 2, “Management’s Discussion and Analysis of Financial Condition and

Results of Operations,” as well as in our condensed consolidated financial statements and the related notes

included in Part I, Item 1, “Financial Statements,” within this Quarterly Report. In addition, you should carefully

consider the risks and uncertainties described in Part I, Item 1A, “Risk Factors,” of our 2026 Annual Report, as well

as in our other public filings with the SEC. If any of the identified risks are realized, our business, results of

operations, financial condition, liquidity, and prospects could be materially and adversely affected. In that case, the

trading price of our common stock may decline, and you could lose all or part of your investment. In addition, other

risks of which we are currently unaware, or which we do not currently view to be material, could have a material

adverse effect on our business, results of operations, financial condition, liquidity, and prospects.

During the three months ended September 30, 2026, there were no material changes to the risks and uncertainties

described in Part I, Item 1A, “Risk Factors,” of our 2026 Annual Report.

Table of Contents 38

Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Unregistered Sales of Equity Securities

None.

Use of Proceeds

Not applicable.

Purchases of Equity Securities by the Issuer and Affiliated Purchasers

Our Board of Directors (Board) has approved a stock repurchase program which authorizes us to repurchase

shares of our common stock in the open market or in privately negotiated transactions, subject to market conditions,

applicable legal requirements, and other factors (collectively, the stock repurchase program). Our Board last

approved an additional authorization of $3,500,000 on May 20, 2026, to repurchase shares of our common stock

under the same conditions as our prior stock repurchase program. As of September 30, 2026, the aggregate

remaining authorization under our stock repurchase program is $4,412,139.

Our stock repurchase program does not obligate us to acquire any amount of common stock and may be

suspended at any time at our discretion.

Stock repurchase activity under our stock repurchase program during the three months ended September 30, 2026,

was as follows:

Total Number of Shares Repurchased (1) (2)Weighted Average Price per ShareDollar Value of Shares Repurchased (2) (3)Dollar Value of Shares Remaining for Repurchase (2)
July 1 - July 31, 20261,240,372$102.52$127,167$4,584,249
August 1 - August 31, 20261,214,67892.30112,1114,472,138
September 1 - September 30, 2026740,77381.0059,9994,412,139
Total3,195,82393.65$299,2774,412,139

(1) All share repurchases were made pursuant to our stock repurchase program in open-market transactions.

(2) May not calculate on rounded amounts.

(3) The dollar value of shares repurchased excludes the cost of broker commissions, excise taxes, and other costs.

Subsequent to September 30, 2026, through October 8, 2026, we repurchased 187,375 shares of our common

stock at a weighted average price of $80.05 per share for $15,000. As of October 8, 2026, we had $4,397,139

remaining authorized for repurchases under the stock repurchase program.

Refer to the section titled “Liquidity” under Part I, Item 2, “Management’s Discussion and Analysis of Financial

Condition and Results of Operations,” and Note 10, “Stockholders’ Equity,” of our condensed consolidated financial

statements in Part I, Item 1 within this Quarterly Report, for further information on our stock repurchase program.

Table of Contents 39

Previous: Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK · Next: Item 5. OTHER INFORMATION